 |
Tranzyme Pharma Announces First Quarter 2013 Financial Results
May 9, 2013
|
20.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics, today announced its financial results for the first quarter ended March 31, 2013.Select First Quarter 2013 Financial Results...
|
|
Tranzyme Pharma to Report First Quarter 2013 Financial Results
May 2, 2013
|
7.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report first quarter 2013 financial results after the close of the market on Thursday, May 9, 2013.About Tranzyme Pharma
Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commerci...
|
|
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement
Apr 23, 2013
|
26.0 KB |
|
| |
$20M Committed PIPE Financing to Close With Merger
— Joint Conference Call Scheduled for April 24, 2013 at 8:00am ET —
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel...
|
|
Tranzyme Pharma Announces Fourth Quarter and Full-Year 2012 Financial Results
Mar 28, 2013
|
16.7 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., March 28, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics, today announced its financial results for the fourth quarter and year ended December 31, 2012.Select Fourth Quarter 2012 Financial Res...
|
|
Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results
Mar 13, 2013
|
7.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report fourth quarter and full-year 2012 financial results after the close of the market on Thursday, March 28, 2013.About Tranzyme Pharma
Tranzyme Pharma is a biopharmaceutical company focused on discovering, de...
|
|
Tranzyme Pharma Announces Exploration of Strategic Alternatives
Feb 8, 2013
|
10.5 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction to maximize value to its stockholders.
...
|
|
Tranzyme Pharma Promotes David Moore to Chief Business Officer
Jan 15, 2013
|
10.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer.
"Dave has provided meaningful contributions and leadership since joining Tranzyme said Vipin Garg, PhD, Tranzyme's President and Chief Executive Officer. I look forward to wo...
|
|
Tranzyme Pharma Announces Successful Completion of Drug Discovery Collaboration With Bristol-Myers Squibb
Jan 4, 2013
|
11.7 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule macrocyclic compounds, today announced the successful completion of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb. As a res...
|
|
Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results
Dec 17, 2012
|
8.3 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned ...
|
|
Tranzyme Pharma Announces Resignation of Chief Financial Officer
Dec 5, 2012
|
10.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Richard I. Eisenstadt, Vice President, Finance and Chief Financial Officer, has resigned effective January 4, 2013, to pursue a new career opportunity.
"On behalf of the entire team at Tranzyme Pharma, I would like to thank Rich fo...
|
|
Tranzyme Pharma to Speak at Piper Jaffray Healthcare Conference
Nov 20, 2012
|
8.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will speak at the 24th Annual Piper Jaffray Healthcare Conference taking place at the New York Palace hotel, New York, NY November 27-28, 2012. Tranzyme's session is scheduled for Wednesday, No...
|
|
Tranzyme Pharma Announces Top-Line Results of TZP-102 Phase 2b Trial
Nov 15, 2012
|
15.2 KB |
|
| |
Preliminary Analysis Indicates Trial Did Not Meet Primary EndpointTranzyme to Host Conference Call Today at 8:00 am ET
RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced top-line results of the preliminary analysis of the first of two Phase 2b trials assessing the safety and efficacy ...
|
|
Tranzyme Pharma Announces Third Quarter 2012 Financial Results
Nov 8, 2012
|
18.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) motility disorders, today announced its financial results and business update for...
|
|
Tranzyme Pharma to Host Third Quarter 2012 Financial Results Conference Call on Friday, November 9, 2012
Oct 25, 2012
|
9.4 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, November 9, 2012 at 8:30 am ET to discuss third quarter 2012 financial results. The Company will report third quarter 2012 financial results after the close of the market on Thursday, November...
|
|
Tranzyme Pharma to Present at BIO Investor Forum on October 10, 2012
Oct 3, 2012
|
8.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the 11th Annual BIO Investor Forum taking place at the Palace Hotel in San Francisco, CA October 9-10, 2012. Tranzyme's presentation is scheduled for Wednesday, October 10th at 1...
|
|
Tranzyme Pharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of $11.5 Million Registered Direct Offering of Common Stock
Sep 18, 2012
|
11.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that it has closed the previously announced underwritten registered direct offering of approximately 3.0 million shares of its common stock at a price of $3.85 per share for gross proceeds, including the over-allotment option, of approxima...
|
|
Tranzyme Pharma Raises $10 Million in Registered Direct Offering
Sep 13, 2012
|
11.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it has agreed to sell approximately 2.6 million shares of its common stock at a price of $3.85 per share in a registered direct offering. The offering will raise gross proceeds to Tranzyme of approximately $10.0 million before deduct...
|
|
Tranzyme Pharma to Present at the Stifel Nicolaus Healthcare Conference on September 5, 2012
Aug 23, 2012
|
8.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the Stifel Nicolaus Healthcare Conference taking place at the Four Seasons Hotel in Boston, MA September 5-6, 2012. Tranzyme's presentation is scheduled for Wednesday, September ...
|
|
Company Completes Patient Enrollment in TZP-102 Phase2b Trial
Aug 9, 2012
|
19.5 KB |
|
| |
...
|
|
Tranzyme Pharma Announces Second Quarter 2012 Financial Results
Aug 9, 2012
|
19.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) motility disorders, today announced its financial results and business update fo...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
